Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Retained Earnings: 2020-2025

Historic Retained Earnings for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to -$1.2 billion.

  • Arcutis Biotherapeutics' Retained Earnings fell 3.99% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 3.99%. This contributed to the annual value of -$1.1 billion for FY2024, which is 14.26% down from last year.
  • Arcutis Biotherapeutics' Retained Earnings amounted to -$1.2 billion in Q3 2025, which was up 0.64% from -$1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Retained Earnings peaked at -$238.0 million during Q1 2021, and registered a low of -$1.2 billion during Q2 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$1.1 billion (2024), whereas its average is -$1.0 billion.
  • Data for Arcutis Biotherapeutics' Retained Earnings shows a maximum YoY tumbled of 152.39% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Retained Earnings stood at -$408.3 million in 2021, then tumbled by 76.29% to -$719.8 million in 2022, then tumbled by 36.41% to -$981.9 million in 2023, then decreased by 14.26% to -$1.1 billion in 2024, then declined by 3.99% to -$1.2 billion in 2025.
  • Its last three reported values are -$1.2 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.1 billion during Q1 2025.